NCT06112665View on ClinicalTrials.gov

ToFAcitinib in Early Active Axial SpondyloarThritis:

PHASE4RecruitingINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

November 10, 2023

Primary Completion Date

March 31, 2025

Study Completion Date

June 30, 2026

Conditions
Axial Spondyloarthritis
Interventions
DRUG

Tofacitinib 5 MG

Patients receive Tofacitinib and Naproxene

Trial Locations (1)

Unknown

RECRUITING

Charité Universitätsmedizin Berlin, Berlin

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Charite University, Berlin, Germany

OTHER

NCT06112665 - ToFAcitinib in Early Active Axial SpondyloarThritis: | Biotech Hunter | Biotech Hunter